Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/715446/000151316219000202/form10q.htm
April 2022
March 2022
December 2021
October 2021
October 2021
June 2021
May 2021
April 2021
March 2021
January 2021
Document And Entity Information - shares | 9 Months Ended | |
---|---|---|
Jul. 31, 2019 | Sep. 05, 2019 | |
Document Information Line Items | ||
Entity Registrant Name | Anixa Biosciences Inc | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --10-31 | |
Entity Common Stock, Shares Outstanding | 20,207,261 | |
Amendment Flag | false | |
Entity Central Index Key | 0000715446 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Jul. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Ex Transition Period | false | |
Entity Interactive Data Current | Yes |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/715446/000151316219000202/form10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
Research and Development Expenses Research and development expenses are related to the development of our cancer diagnostics and therapeutics programs and decreased by approximately $1,856,000 to approximately $1,086,000 in the three months ended July 31, 2019, from approximately $2,942,000 in the three months ended July 31, 2018.
Accordingly, the earnings process from these licenses was complete and 100% of the revenue was recognized upon execution of the license agreement.
Accordingly, the earnings process from these licenses was complete and 100% of the revenue was recognized upon execution of the license agreement.
As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is probable and all other revenue recognition criteria have been met.
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $10,000 to approximately $148,000 in the nine months ended July 31, 2019, from approximately $158,000 in the nine months ended July 31, 2018, as Certainty's net loss decreased.
The net loss attributable to...Read more
Cash provided by financing activities...Read more
Interest income increased by approximately...Read more
Interest income increased by approximately...Read more
The decrease in Certainty's net...Read more
The decrease in Certainty's net...Read more
We can give no assurance...Read more
As a result, our cash,...Read more
General and Administrative Expenses General...Read more
27 General and Administrative Expenses...Read more
The impairment in carrying amount...Read more
The increase in research and...Read more
Amortization of patents decreased by...Read more
Additionally, the sale of equity...Read more
29 We believe that, of...Read more
Inventor royalties, contingent legal fees,...Read more
The decrease in amortization of...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001513162-19-000202
Submitted to the SEC: Fri Sep 06 2019 1:01:43 PM EST
Accepted by the SEC: Fri Sep 06 2019
Period: Wednesday, July 31, 2019
Industry: Medical Laboratories